Lumbrokinase -- A Potent and Stable Fibrin--Specific Plasminogen Activator

Verma, Mahendra Kumar; Pulicherla, K. K.
June 2011
International Journal of Bio-Science & Bio-Technology;Jun2011, Vol. 3 Issue 2, p57
Academic Journal
Cardio and cerebrocascular disorders lead to about 26 million deaths every year around the world. Cardio and cerebrovaccular disorders have not only high mortality rate across the globe but also leading to subsequent complication such as thrombolysis could favorably influence the outcome of such life-threatening disorder as myocardial infarction, cerebrovascular thrombosis, and venous thromboembolism. Our healthy system is capable to overcome to these consequences but when there is imbalance of defensive and aggressive factor in our system result come as blood clot in systemic circulation. Now role of thrombolytic agents come in picture as artificial plasminogen activators that convert plasminogen, an inactive form of plasmin to dissolve the clot by converting inactive plasminogen in active plasmin. Plasmin dissolves the fibrin blood clot, but may also degrade normal components of the hemostatic system which can further create another life threatening consequence and death also so there is always need of such an agent who specifically dissolved clot which are in circulation but not others.


Related Articles

  • Development of New Fibrinolytic Agents. Ueshima, Shigeru; Matsuo, Osamu // Current Pharmaceutical Design;Mar2006, Vol. 12 Issue 7, p849 

    Since the activation of coagulation system and platelets triggers the thrombosis, the agents possessing anticoagulation or anti-platelet function have been used for the antithrombotic procession actions. However, in the physiological condition, the fibrinolytic system serves as antithrombotic,...

  • Plasminogen Activators in the Complex Therapy of Cerebrovascular Disorders. Rozhchenko, L. V. // Pharmaceutical Chemistry Journal;Jun2003, Vol. 37 Issue 6, p277 

    Investigates the plasminogen activators in the complex therapy of cerebrovascular disorders. Formation of plasmin due to plasminogen activators; Cause of proteolysis of fibrin and fibrinogen; Observation of the complex compound of heparin with hormones and components of the blood coagulation system.

  • Evolutionary Trend of Thrombolytics. Kumar, Anmol; Pulicherla, K. K.; Ram, K. Seetha; Rao, K. R. S. Sambasiva // International Journal of Bio-Science & Bio-Technology;Dec2010, Vol. 2 Issue 4, p51 

    Thrombolytic drugs have been used in the clinical arena to treat a wide variety of venous and arterial thromboembolic disorders which are a main cause of death. Thrombolytic molecules are plasminogen activators that convert the inactive plasminogen to the active proteolytic enzyme plasmin which...

  • Streptokinase as Fibrinolytic Agent. Hamid, Mohsina; Khalil-Ur-Rehman; Asghar, Muhammad; Sarwar, Muhammad // Asian Journal of Chemistry;2012, Vol. 24 Issue 4, p1809 

    Accumulation of fibrin in the blood vessels usually results in the thrombosis, leading to myocardial infarction and other cardiovascular diseases. For thrombolytic therapy microbial fibrinolytic enzymes have now attracted much more attention than typical thrombolytic agents because of the high...

  • The effects of whole body vibration and exercise on fibrinolysis in men. Boyle, Leryn J.; Nagelkirk, Paul R. // European Journal of Applied Physiology;Nov2010, Vol. 110 Issue 5, p1057 

    Whole body vibration (WBV) is a novel modality that has been demonstrated to enhance muscular and cardiovascular functions reported to increase fibrinolytic activity. The purpose of this study was to examine the fibrinolytic response to WBV and exercise in men. Twenty healthy males...

  • Sonothrombolysis in the Management of Acute Ischemic Stroke. Rubiera, Marta; Alexandrov, Andrei V. // American Journal of Cardiovascular Drugs;2010, Vol. 10 Issue 1, p5 

    Multiple in vitro and animal models have demonstrated the efficacy of ultrasound to enhance fibrinolysis. Mechanical pressure waves produced by ultrasound energy improve the delivery and penetration of thro (recombinant tissue plasminogen activator [tPA]) inside the clot. In human stroke, the...

  • Associations of Thrombophilia, Hypofibrinolysis, and Retinal Vein Occlusion. Glueck, Charles J.; Ping Wang; Bell, Howard; Rangaraj, Venkat; Goldenberg, Naila // Clinical & Applied Thrombosis/Hemostasis;Oct2005, Vol. 11 Issue 4, p375 

    We prospectively assessed whether thrombophilia and hypofibrinolysis, amplified by thrombophilic hormone replacement therapy (HRT), were associated with retinal vein occlusion (RVO). We studied 44 cases (18 men, 26 women), ≥ 3 months after RVO, 42 with central RVO, 2 with branch RVO, in...

  • Changes of Gene Expression by Lysophosphatidylcholine in Vascular Endothelial Cells: 12 Up-Regulated Distinct Genes Including 5 Cell Growth-Related, 3 Thrombosis-Related, and 4 Others1. Sato, Naoaki; Kokame, Koichi; Shimokado, Kentaro; Kato, Hisao; Miyata, Toshiyuki // Journal of Biochemistry;1998, Vol. 123 Issue 6, p1119 

    Lysophosphatidylcholine (lysoPC), a component of oxidatively modified lipoproteins, is present in atherosclerotic lesions, and its proatherogenic properties have been demonstrated. To gain an insight into lysoPC-mediated endothelial gene expression, we applied nonradioactive differential display...

  • Thrombolytic Therapy. Baker Jr., William F. // Clinical & Applied Thrombosis/Hemostasis;Oct2002, Vol. 8 Issue 4, p291 

    The therapeutic use of thrombolytic agents is the natural result of the increasing understanding of the pathophysiologic mechanisms underlying normal and deranged thrombosis and fibrinolysis. Plasminogen activators capable of increasing the production of plasmin exhibit considerable efficacy in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics